Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.67 |
| ▸ | GSK3A | P49840 | 2/20 | 0.67 |
| ▸ | CDC7 | O00311 | 1/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | PAK4 | O96013 | 1/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | PRKCG | P05129 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093702 | 0.93 | ALK (0.70) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4103561 | 0.93 | ULK1 (0.67) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4089503 | 0.92 | ALK (0.70) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL380944 | 0.92 | ULK1 (0.88) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4089370 | 0.90 | ALK (0.68) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4096350 | 0.89 | ULK1 (0.68) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4088361 | 0.88 | ULK1 (0.72) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4100115 | 0.88 | ALK (0.63) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4100866 | 0.86 | ALK (0.66) | ULK1ALKEGFRGSK3ACDC7 | |
| SCHEMBL4099214 | 0.86 | ULK1 (0.57) | ULK1ALKEGFRGSK3ACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | claimed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ULK1 1714/4885ALK 2060/4885EGFR 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.